Deal Value
Undisclosed
Announced
Friday, September 18, 2026
Deal Details
Anew Labs, a ByteDance spin off focused on AI driven drug design, raised US$290 million from Chinese venture firms with ByteDance retaining majority ownership.
A financial investment providing capital in exchange for equity or strategic partnership.
Related Analysis
Anthropic Built a Wet Lab. The Bottleneck in AI Drug Discovery Was Never the Model.
In one week a frontier lab confirmed it runs physical experiments, Washington put money behind AI replacing animal tests, and a ByteDance spin-off raised $290 million. All three are bets on verification, and that changes how to judge an AI biology company.
Meta's $2 Billion Manus Deal Was Blocked. Manus Is Now Asking $4 Billion.
A failed exit is supposed to leave a startup damaged. Manus is in talks at double the price, with a different set of buyers. Here is what that says about where China-rooted AI companies can sell, and to whom.
Related Deals
Unknown → Anthropic
Unknown → Meta
PeerCapital → Karta AI
IDG Capital → Today AI
Unknown → Sarvam AI
Shanghai State Investment Pilot Fund → Pongbot